Price of APP Pharmaceuticals' heparin goes up
Faced with increased costs of supplying uncontaminated heparin, APP Pharmaceuticals adjusts the cost of its product.
3013Background: Pembro (anti–PD-1), ipi (anti–CTLA-4), and PEG-IFN (cytokine) are approved as monotherapy for treating melanoma. KEYNOTE-029 (NCT02089685) is a first-in-human, phase 1 study that in...